Clinical Trials List
2017-02-01 - 2027-02-01
Phase III
Terminated5
ICD-10C50
Malignant neoplasm of breast
ICD-9170.0
Malignant neoplasm of bones of skull and face, except mandible
-
Trial Applicant
Syneos Health
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Chieh-Han Chuang Division of General Surgery
- 甘蓉瑜 Division of General Surgery
- Fu Ouyang Division of General Surgery
- Fang-Ming Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 金光亮 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- 邱仁輝 Division of General Surgery
- 林燕淑 Division of General Surgery
The Actual Total Number of Participants Enrolled
8 Stop recruiting
Audit
None
Co-Principal Investigator
- MING-YANG WANG Division of General Surgery
- SUNG-HSIN KUO Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 蔡立威 Division of General Surgery
- 張端瑩 Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- 林柏翰 Division of General Internal Medicine
- Wei-Wu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
- Kuo-Ting Lee Division of General Surgery
- Wu-Chou Su Division of General Internal Medicine
- Zhu-Jun Loh Division of General Surgery
- Ya-Ping Chen Division of General Internal Medicine
- Jui-Hung Tsai Division of General Internal Medicine
- Ya-Ting Hsu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
115 participants
-
Global
4600 participants
